UK Edition
AdvertiseSubmit Company
Pharma JournalEvidence-Based Pharmaceutical Intelligence
GENOMICS & PRECISION MEDICINE

Agilent Technologies

A

Agilent Technologies

Genomics & Precision MedicineSanta Clara, United States
Visit Website

About Agilent Technologies

Agilent Technologies traces its origins to Hewlett-Packard, spinning off in 1999 to become an independent leader in life science, diagnostics, and applied chemical markets. Headquartered in Santa Clara, California, and listed on the New York Stock Exchange under the ticker A, the company operates across more than 35 countries and serves customers in pharmaceutical research, clinical diagnostics, food safety, environmental testing, and forensics.

Analytical Instruments & Laboratory Platforms

Agilent is best known for its analytical instrumentation portfolio, which spans liquid chromatography, gas chromatography, mass spectrometry, spectroscopy, and genomics. Its liquid chromatography-mass spectrometry systems are widely used in pharmaceutical quality control, drug discovery, and bioanalytical research. The Infinity II LC series and the 6400 series triple quadrupole mass spectrometers are established reference instruments in laboratories worldwide. The company also supplies consumables, columns, reagents, and software that integrate with its hardware to support complete analytical workflows.

Genomics & Diagnostics Solutions

Through its diagnostics and genomics group, Agilent provides SureSelect target enrichment systems, oligonucleotide synthesis, microarray platforms, and next-generation sequencing library preparation tools. These products serve clinical genomics, oncology research, and companion diagnostics development. Agilent's Dako immunohistochemistry portfolio, acquired as part of earlier acquisitions, is used in pathology laboratories to support cancer diagnostics and is an important component of its presence in clinical settings.

The company serves a broad customer base that includes global pharmaceutical and biotechnology companies, academic research institutions, government laboratories, and clinical reference labs. Its CrossLab services division offers enterprise-level laboratory management, instrument maintenance, and informatics, helping organisations manage complex multi-vendor laboratory environments.

Agilent's software and informatics offerings, including the OpenLab chromatography data system, are integrated into regulated pharmaceutical manufacturing and quality environments where audit trails and compliance are essential. The company continues to invest in expanding its capabilities in precision medicine, cell analysis, and spatial biology.

Further information is available at agilent.com.

Similar Companies

More in Genomics & Precision Medicine

E

Eurofins Scientific

Eurofins Scientific is one of the world's largest networks of independent laboratories, offering an exceptionally broad range of testing, bioanalytical, and discovery services to the pharmaceutical, food, environmental, and consumer products industries. Founded in 1987 in Nantes, France, the company has grown from a specialist in food authenticity testing into a global life science services powerhouse, now operating more than 900 laboratories across over 60 countries. Pharmaceutical & Bioanalytical Testing Services Within the pharmaceutical sector, Eurofins provides contract testing services spanning the full drug development and manufacturing lifecycle. Its offerings include physicochemical analysis, microbiology and sterility testing, stability studies, method development and validation, and raw material testing. The company also operates a significant bioanalytical division, supporting clinical trials through regulated bioanalysis, pharmacokinetics, and immunogenicity testing. These capabilities make it a widely used partner for both large pharmaceutical companies and emerging biotech firms seeking outsourced laboratory expertise. Genomics, CDMO Support & Discovery Sciences Eurofins has built a substantial presence in genomics services, including DNA sequencing, genotyping, gene synthesis, and next-generation sequencing, operating through its dedicated Eurofins Genomics brand. The group also supports CDMO partners and sponsors with quality control testing for biologics, biosimilars, and advanced therapy medicinal products. Its discovery sciences arm offers screening, ADME-Tox, and in vitro pharmacology services, enabling earlier-phase research outsourcing alongside its late-stage and commercial manufacturing quality work. Listed on Euronext Brussels under the ticker ERF, Eurofins is headquartered in Luxembourg and operates with revenues that place it firmly among the leading life science services groups globally. Its decentralised laboratory network is a deliberate structural choice, allowing local regulatory expertise and rapid service delivery alongside the scale benefits of a multinational organisation. The company serves clients across agrochemical, environmental, forensic, and clinical diagnostics sectors in addition to its core pharmaceutical audience. Further information is available at eurofins.com.

View profile
V

Vertex Pharmaceuticals

Vertex Pharmaceuticals transformed cystic fibrosis from a life-limiting condition into one manageable with daily oral therapy, establishing itself as the defining force in CF treatment worldwide. Founded in 1989 and headquartered in Boston, Massachusetts, Vertex is listed on Nasdaq under the ticker VRTX and has grown into one of the most closely watched names in specialty pharmaceuticals. Cystic Fibrosis Leadership Vertex's dominance in cystic fibrosis is built on a portfolio of CFTR modulator therapies, culminating in Trikafta (known as Kaftrio in Europe), a triple-combination treatment eligible for the vast majority of CF patients aged two and above with at least one F508del mutation. The clinical and commercial success of this franchise has made Vertex the standard-bearer for precision medicine in a rare disease setting, with regulatory approvals secured across the United States, European Union, United Kingdom, and numerous other markets. Pipeline Expansion Beyond CF Having secured its financial foundation through CF, Vertex has invested heavily in diversifying its pipeline across pain, kidney disease, type 1 diabetes, and haematology. Its non-opioid pain programme, centred on a Nav1.8 sodium channel inhibitor, reached late-stage trials and attracted significant attention from the broader industry as a potential alternative to opioid analgesics. In haematology, Vertex partnered with CRISPR Therapeutics to develop Casgevy, the first approved CRISPR-based gene-editing therapy, indicated for sickle cell disease and transfusion-dependent beta thalassaemia. This approval marked a milestone not only for Vertex but for the entire field of gene editing. The company maintains major research and commercial operations across the United States, United Kingdom, and Europe, with a significant presence in London following its acquisition of a Cambridge, UK research hub. Vertex employs thousands of staff globally across research, development, medical affairs, and commercial functions. Further information is available at vrtx.com.

View profile
Q

QIAGEN

QIAGEN pioneered the column-based nucleic acid purification method that became the global standard for molecular biology, and today its sample-to-insight technologies are used in more than 500,000 laboratories across 160 countries. Founded in 1984 in Düsseldorf, Germany, and listed on both the Nasdaq and the Frankfurt Stock Exchange under the ticker QGEN, the company occupies a singular position in life sciences: it sits at the very front of the analytical workflow, ensuring that the biological sample reaching any downstream instrument is clean, consistent, and ready for meaningful results. Sample Technologies & Molecular Diagnostics The company's portfolio spans consumables, automated instruments, and bioinformatics, unified by the principle that sample quality determines everything that follows. Its QIAamp, RNeasy, and DNeasy product families are reference standards in research and clinical settings alike. The QIAsymphony and QIAcube platforms automate extraction workflows from research benches through to hospital laboratories, reducing hands-on time and variability. In molecular diagnostics, QIAGEN markets CE-marked and FDA-cleared assays covering infectious disease detection, oncology companion diagnostics, and human identification, with the QIAstat-Dx syndromic testing system enabling rapid, near-patient panel testing for respiratory and gastrointestinal pathogens. Bioinformatics & Precision Medicine Through its QIAGEN Digital Insights division, the company provides bioinformatics software that connects raw sequencing output to clinical and biological interpretation. Ingenuity Pathway Analysis and the CLC Genomics Workbench are widely used in both pharmaceutical research and translational medicine. The QCI Interpret platform supports variant classification for oncology and rare-disease workflows, positioning QIAGEN as a partner across the continuum from discovery research to regulated diagnostics. Therapy areas served include oncology, infectious disease, immunology, and forensics, with a growing presence in liquid biopsy and companion diagnostic development for pharmaceutical partners. Headquartered in Venlo, Netherlands, with operational hubs in Hilden, Germany, and Germantown, Maryland, QIAGEN employs approximately 6,000 people worldwide and generates revenues in excess of two billion US dollars annually. The company serves customers in pharmaceuticals, biotechnology, clinical diagnostics, applied testing, and academic research. Further information is available at qiagen.com.

View profile
AdvertisementTeksyte LTD

List Your Company

Showcase your company to thousands of pharma professionals.

Submit Listing

Advertise With Us

Reach decision-makers in the pharmaceutical industry.

Learn More

We use cookies and analytics to understand how the site is used and to keep the service free. Choose Accept All to allow this, or Essential Only to use just the cookies we need to keep the site working. You can change your choice any time in our Cookie Policy